ConCallIQ
Go Pro
Home › Sanjivani Paranteral › Guidance

Sanjivani Paranteral Management Guidance Tracker

8 forward-looking guidance items tracked across 2 quarters.

Revenue

Q3 FY26FY27 standalone revenue target of ₹90 croreTracked

Management expects base business (standalone) to reach ₹90 crore in FY27, implying ~20% growth over FY26 estimated ₹73-75 crore.

Q3 FY26FY27 SPL Infusion revenue target of ₹60-65 croreTracked

The Pune IV fluids JV is expected to contribute ₹60-65 crore in FY27, up from ₹1.2 crore in Q3 FY26.

Q4 FY26FY27 Base Business Revenue TargetTracked

Management guided for base business revenue of ₹80-85 crore in FY27.

Q4 FY26FY27 IV Facility Revenue TargetTracked

Management guided for Pune IV fluids plant revenue of ₹60-65 crore in FY27.

Growth

Q3 FY26SPL Infusion capacity utilization to reach 40-50% by FY27Tracked

Current utilization is 23-27%; management targets 40-50% by FY27 as product approvals ramp up.

Margins

Q3 FY26Base business EBITDA margin of 16-17% for FY26Active

Management expects standalone EBITDA margin to remain in the 16-17% range for the full year, consistent with 9-month trends.

Q4 FY26IV Facility EBITDA Margin TargetTracked

Management expects IV facility to achieve EBITDA margins of 17-18% on an annualized basis in FY27.

Q4 FY26Base Business EBITDA Margin GuidanceTracked

Management guided base business EBITDA margins in the range of 15.5-16.5% for FY27.